The finding that phosphoinositide-3-OH kinase δ restrains the antitumour immune response by promoting the action of suppressive immune cells may broaden the applicability of drugs targeting this enzyme to multiple cancers. See Letter p.407
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Ali, K. et al. Nature 510, 407–411 (2014).
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. Nature Rev. Mol. Cell Biol. 11, 329–341 (2010).
Hirsch, E., Ciraolo, E., Franco, I., Ghigo, A. & Martini, M. Oncogene http://dx.doi.org/10.1038/onc.2013.265 (2013).
Okkenhaug, K. Annu. Rev. Immunol. 31, 675–704 (2013).
Fruman, D. A. & Cantley, L. C. N. Engl. J. Med. 370, 1061–1062 (2014).
Couzin-Frankel, J. Science 342, 1432–1433 (2013).
Sakaguchi, S., Miyara, M., Costantino, C. M. & Hafler, D. A. Nature Rev. Immunol. 10, 490–500 (2010).
Putz, E. M. et al. PLoS ONE 7, e40852 (2012).
About this article
Cite this article
Hirsch, E., Novelli, F. Natural-born killers unleashed. Nature 510, 342–343 (2014). https://doi.org/10.1038/nature13503